FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine and concerns recombinant viral vaccines. Substance of the inventions involves recombinant viral vaccines containing a recombinant poxvirus vector which expresses in vivo at least one heterological sequence of a nucleotide which codes an antigen and one 1H-imidazo [4,5-c] quinoline-4-amine derivative with said poxvirus vector being MVA. Particularly, the presented invention discloses the combined vaccines which combine the recombinant viral vectors MVA containing a nucleotide coding one or more HPV antigens which are able to intensify the immune response which is observed in in vivo under said recombinant viral vectors.
EFFECT: advantage of the group of inventions consists in intensifying the immune responses.
18 cl, 2 ex, 10 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| BIOMARKER FOR PATIENT MONITORING | 2010 |
|
RU2555340C2 |
| SOLUBLE ICAM-A AS BIOMARKER FOR PREDICTION OF THERAPEUTIC RESPONSE | 2010 |
|
RU2574984C2 |
| BIOMARKER FOR PATIENT SELECTION AND RELATED METHODS | 2010 |
|
RU2552292C2 |
| BIOMARKER FOR PATIENT'S MONITORING | 2010 |
|
RU2542435C2 |
| PAPILLOMAVIRUS E2 POLYPEPTIDES USED FOR VACCINATION | 2008 |
|
RU2482189C2 |
| METHOD OF OBTAINING POXVIRUSES AND COMPOSITIONS OF POXVIRUSES | 2007 |
|
RU2551982C2 |
| VECTORS FOR MULTIPLE GENE EXPRESSION | 2008 |
|
RU2462513C2 |
| BIOMARKER FOR SELECTING PATIENTS AND RESPECTIVE QUESTIONS | 2009 |
|
RU2517719C2 |
| METHOD TO PRODUCE POX VIRUSES AND COMPOSITIONS OF POX VIRUSES | 2007 |
|
RU2489486C2 |
| PRODUCTION OF POX VIRUSES AND COMPOSITION OF POX VIRUSES | 2013 |
|
RU2581910C2 |
